Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $11.21, but opened at $9.26. Gyre Therapeutics shares last traded at $9.74, with a volume of 965,629 shares traded.
Analyst Upgrades and Downgrades
Separately, Noble Financial initiated coverage on Gyre Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating on the stock.
Get Our Latest Stock Analysis on GYRE
Gyre Therapeutics Stock Performance
The stock's 50-day moving average is $9.00 and its 200 day moving average is $10.78. The stock has a market capitalization of $850.67 million, a PE ratio of 452.90 and a beta of 1.90.
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported $0.03 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.03. The firm had revenue of $22.06 million for the quarter, compared to the consensus estimate of $28.40 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in Gyre Therapeutics during the 4th quarter worth $1,225,000. American Century Companies Inc. acquired a new stake in Gyre Therapeutics during the 1st quarter worth $184,000. Northern Trust Corp boosted its stake in Gyre Therapeutics by 9.1% during the 4th quarter. Northern Trust Corp now owns 103,382 shares of the company's stock worth $1,251,000 after purchasing an additional 8,624 shares during the period. Barclays PLC boosted its stake in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after purchasing an additional 6,855 shares during the period. Finally, Advantage Alpha Capital Partners LP boosted its stake in Gyre Therapeutics by 54.0% during the 1st quarter. Advantage Alpha Capital Partners LP now owns 13,663 shares of the company's stock worth $105,000 after purchasing an additional 4,790 shares during the period. Hedge funds and other institutional investors own 23.99% of the company's stock.
About Gyre Therapeutics
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
